CLINICAL TRIALS IN ONCOLOGY

肿瘤学临床试验

• 批准号: 2700370
• 负责人: LAWRENCE H EINHORN
• 金额: $ 55.83万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-07-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2700370
• 关键词: 5 fluorouridine; antiemetics; antineoplastics; azacitidine; bleomycin; bone marrow transplantation; breast neoplasms; cis platinum compound; clinical trials; clone cells; colon neoplasms; colony stimulating factor; combination chemotherapy; dosage; drug resistance; drug screening /evaluation; etoposide; flow cytometry; hematopoietic growth factor; human subject; human therapy evaluation; ifosfamide; leucovorin; levamisole; lung neoplasms; mitoxantrone; neoplasm /cancer chemotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; oncology; testis neoplasms

Dr. Lawrence H. Einhorn will continue his studies in Clinical Cancer Research through the Outstanding Investigator Grant. Pivotal studies will continue to be done in patients with testicular cancer. Dr. Einhorn and co-investigators will evaluate a new aggressive five drug regimen as initial therapy for patients with advanced testicular cancer. New and innovative approaches for salvage therapy of testicular cancer will also be carefully studied. In addition, correlatives clinical studies will be done evaluating antiemetics and hematopoietic growth factors. In addition, Dr. Einhorn and colleagues will continue to participate in clinical trials for common malignancies such as colorectal cancer, lung cancer, breast cancer, etc. Recognizing the importance of these trials and the frequent necessity to perform them at the community level, Dr. Einhorn helped form the consortium of community oncologist in Indiana and surrounding areas called the Hoosier Oncology Group. Indiana University is a research base for this organization and Dr. Einhorn is the Chief Scientific Officer. One of the exciting new areas of interest has been the development of a new protocol in metastatic bladder cancer. This phase II study will evaluate the combination of vinblastine + ifosfamide + gallium in patients with metastatic bladder cancer.

Lawrence H. Einhorn博士将继续他的临床癌症研究 通过杰出的调查员赠款进行研究。 关键研究 睾丸癌患者将继续进行。 博士 Einhorn和共同研究人员将评估一种新的侵略性五种药物 治疗疗法作为晚期睾丸癌患者的初始治疗。 睾丸癌的挽救疗法的新创新方法 还将仔细研究。 另外，相关型临床 将完成评估抗神经剂和造血生长的研究 因素。 此外，Einhorn博士及其同事将继续参加 常见恶性肿瘤，例如结直肠癌，肺部的临床试验 癌症，乳腺癌等认识到这些试验的重要性 以及在社区层面上进行频繁的必要性，博士 Einhorn帮助组建了印第安纳州社区肿瘤学家联盟 周围地区称为Hoosier肿瘤学小组。 印第安纳州 大学是该组织的研究基础，Einhorn博士是 首席科学官。 令人兴奋的新领域之一是发展 转移性膀胱癌的新方案。 这项第二阶段研究将 评估葡萄碱 + ifosfamide +甘油的组合 转移性膀胱癌患者。

项目成果

Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial.

西咪替丁治疗转移性黑色素瘤的 II 期试验。

• DOI: 10.1097/00000421-199110000-00007
• 发表时间: 1991
• 期刊: American journal of clinical oncology
• 作者: Mandanas,R;Schultz,S;Scullin,D;Einhorn,LH
• 通讯作者: Einhorn,LH

Ifosfamide in testicular cancer.

异环磷酰胺治疗睾丸癌。

• 发表时间: 1990
• 期刊: Seminars in oncology
• 影响因子: 4
• 作者: LoehrerSr,PJ

Salvage therapy for germ cell tumors.

生殖细胞肿瘤的挽救治疗。

• 发表时间: 1994
• 期刊: Seminars in oncology
• 影响因子: 4
• 作者: Einhorn,LH

Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.

5-氟尿嘧啶与 5-氟尿嘧啶加左旋咪唑治疗转移性结直肠癌的前瞻性随机试验：Hoosier Oncology Group 试验。

• 发表时间: 1998
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research.
• 作者: Bandealy,MT;Gonin,R;Loehrer,PJ;Monaco,F;Einhorn,LH
• 通讯作者: Einhorn,LH

Complicated problems in testicular cancer.

睾丸癌的复杂问题。

• 发表时间: 1988
• 期刊: Seminars in oncology
• 影响因子: 4
• 作者: Einhorn,LH